

10/509095**DT04 Rec'd PCT/PTO 28 SEP 2004**AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions,
and listings, of claims in the application:

LISTING OF CLAIMS:

1. (original) New peptide, selected from the group that
consists of

DVFMKGLSMAKEGV

VFMKGLSMAKEGV

FMKGLSMAKEGV

MKGLSMAKEGV

KGLSMAKEGV

GLSMAKEGV

LSMAKEGV

SMAKEGV

MAKEGV

AKEGV

KEGV

MDVFMKGLSMAKEG

MDVFMKGLSMAKE

MDVFMKGLSMAK

MDVFMKGLSMA

MDVFMKGLSM

MDVFMKGLS

MDVFMKGL

MDVFMKG

MDVFMK
MDVFM
MDVF
DVFMKGLSMAKEG
DVFMKGLSMAKE
DVFMKGLSMAK
DVFMKGLSMA
DVFMKGLSM
DVFMKGLS
DVFMKGL
DVFMKG
DVFMK
DVFM
DVF
GLSMAKEG
GLSMAKE
GLSMAK
GLSMA
GLSM
GLS
GL
LSMAKEG
LSMAKE
LSMAK
LSMA
LSM
LS.

2. (original) Peptides according to claim 1, whereby the individual components are L-amino acids.

3. (original) Peptides according to claim 1, whereby the individual amino acids are D-amino acids.

4. (currently amended) Peptides according to claim 1 [[or 2]], in which the amino acid proline is substituted in the N-terminal position.

5. (currently amended) Peptides according to claim 1 [[or 2]], in which the amino acid proline is substituted in the C-terminal position.

6. (currently amended) Peptides according to claim 1 [[or 2]], in which the amino acid proline is substituted in the N-terminal position and in the C-terminal position.

7. (currently amended) Peptides according to ~~one of claims 1 to 6~~ claim 1, which are acetylated in the N-terminal position.

8. (currently amended) Peptides according to ~~one of claims 1 to 7~~ claim 1, which are amidated in the C-terminal position.

9. (currently amended) Peptides according to claim 7 [[or 8]], which are acetylated in the N-

terminal position and amidated in the C-terminal position.

10. (currently amended) Peptides according to ~~one of claims 1 to 9~~ claim 1, characterized in that the amino acid valine (V) is replaced by the amino acid proline (P).

11. (currently amended) Pharmaceutical agent for use in the therapy of diseases in which the increased occurrence of free radicals plays a pathophysiological role, characterized by at least one peptide according to ~~one of claims 1 to 10~~ claim 1.

12. (currently amended) Pharmaceutical agent for use in the therapy of diseases with acute hypoxia or ischemia in an organ system of the body, in particular in the central nervous system, characterized by at least one peptide according to ~~one of claims 1 to 10~~ claim 1.

13. (currently amended) Pharmaceutical agent for use in the therapy of Recklinghausen-Appelbaum diseases, such as the Hallervorden-Spatz disease, characterized by at least one peptide according to ~~one of claims 1 to 10~~ claim 1.

14. (currently amended) Pharmaceutical agent for use in the therapy of neurodegenerative diseases,

in particular Alzheimer's disease, the Lewy Body variant of Alzheimer's disease, Parkinson's disease, the multisystem atrophy, the Lewy Body dementia or Huntington's chorea, and all states similar to these neurodegenerative diseases, characterized by at least one peptide according to ~~one of claims 1 to 10~~ claim 1 as an active ingredient.

15. (currently amended) Pharmaceutical agent according to ~~one of claims 11 to 14~~ claim 11, which is prepared for oral administration.

16. (currently amended) Pharmaceutical agent according to ~~one of claims 11 to 14~~ claim 11, which is prepared for rectal administration.

17. (currently amended) Pharmaceutical agent according to ~~one of claims 11 to 14~~ claim 11, which is prepared for administration by inhalation.

18. (currently amended) Pharmaceutical agent according to ~~one of claims 11 to 14~~ claim 11, which is prepared for transdermal administration.

19. (currently amended) Pharmaceutical agent according to ~~one of claims 11 to 14~~ claim 11, which is prepared for transmucosal administration.

20. (currently amended) Pharmaceutical agent according to ~~one of claims 11 to 14~~ claim 11, which is prepared for administration via active ingredient-containing implants.

21. (currently amended) Pharmaceutical agent according to ~~one of claims 11 to 14~~ claim 11, which is prepared for intracerebroventricular administration.

22. (currently amended) Pharmaceutical agent according to ~~one of claims 11 to 14~~ claim 11, which is prepared for administration by injection.

23. (currently amended) Pharmaceutical agent according to ~~one of claims 11 to 14~~ claim 11, which is prepared for transnasal administration.

24. (currently amended) Pharmaceutical agent according to ~~one of claims 11 to 14~~ claim 11, which is prepared for administration by infusion.

25-26 (cancelled)